<DOC>
	<DOCNO>NCT01039467</DOCNO>
	<brief_summary>The COMPARE-Adapta study randomize , multi-center , prospective study conduct China . The purpose study compare ability Search AV™+ Managed Ventricular Pacing® ( MVP® ) reduce ventricular pace dual chamber pacemaker-indicated patient . The COMPARE-Adapta study also observe atrial fibrillation ( AF ) burden demonstrate Cardiac Compass® clinical profile Adapta® pacemaker patient .</brief_summary>
	<brief_title>An Comparison Pacemaker Automatic Features Reduction Ventricular Pacing</brief_title>
	<detailed_description>Recent study suggest chronic right ventricular pace associate variety adverse effect patient , particularly intact intermittent atrioventricular ( AV ) conduction . Medtronic Adapta® pacemaker include Managed Ventricular Pacing® , pace mode design promote intrinsic conduction , also Search AV™+ , feature design reduce unnecessary ventricular pace patient intact intermittent AV conduction .</detailed_description>
	<criteria>Signed date study inform consent Class I Class IIa pacemaker indication Geographically stable available followup center length study Age great 18 To implant Adapta dual chamber pacemaker Unwillingness inability give write informed consent participate Study Patient previously implant pacemaker/Implantable CardioverterDefibrillator ( ICD ) /Cardiac Resynchronization Therapy ( CRT ) device Life expectancy less one year Patient mechanical tricuspid heart valve Medical condition preclude test requirement protocol limit study participation Patient persistent 3rd degree atrioventricular ( AV ) block Patient persistent atrial fibrillation ( AF ) Patient neurogenic syncope Patient carotid sinus syndrome Patient hypertrophic obstructive cardiomyopathy Inclusion another clinical trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Managed Ventricular Pacing</keyword>
</DOC>